Get the Stockscreener App
0.834
6.69%
-0.0598
After Hours:
.84
0.006
+0.72%
Invivyd Inc stock is traded at $0.834, with a volume of 2.33M.
It is down -6.69% in the last 24 hours and down -19.03% over the past month.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
See More
Previous Close:
$0.8938
Open:
$0.8772
24h Volume:
2.33M
Relative Volume:
0.55
Market Cap:
$245.70M
Revenue:
$55.87M
Net Income/Loss:
$-77.60M
P/E Ratio:
-2.3381
EPS:
-0.3567
Net Cash Flow:
$-79.46M
1W Performance:
-11.62%
1M Performance:
-19.03%
6M Performance:
-64.96%
1Y Performance:
+13.45%
1-Day Range:
$0.813
$0.88
1-Week Range:
$0.813
$0.9504
52-Week Range:
$0.483
$3.0699
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
209 CHURCH STREET, NEW HAVEN
Compare IVVD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.834 | 257.02M | 55.87M | -77.60M | -79.46M | -0.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-22-25 | Initiated | BTIG Research | Buy |
| Nov-25-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
View All
Invivyd Inc Stock (IVVD) Latest News
New Haven biotech company developing measles treatment as US cases top 2,100 - WFSB
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Value Benchmark Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 2000 Value Benchmark - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell Microcap Index - marketscreener.com
Invivyd, Inc.(NasdaqGM: IVVD) added to Russell 3000E Value Benchmark - marketscreener.com
Invivyd, Inc. Actuals & Estimates (NASDAQ:IVVD) - TradingView
IVVD Forecast — Price Target — Prediction for 2027 - TradingView
Invivyd Shareholder Notice - TMX Newsfile
Lobbying Update: $60,000 of INVIVYD INC. lobbying was just disclosed - Quiver Quantitative
Invivyd, Inc. (IVVD) reports Q1 loss, lags revenue estimates - MSN
Invivyd Inc (IVVD) Institutional Confidence - TradingKey
IVVDInvivyd Inc Latest SEC Filings - Finviz
Invivyd Inc (IVVD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Invivyd Inc (IVVD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Invivyd Inc (IVVD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Invivyd (IVVD) Doses First Participants in Phase 3 Trial for VYD2311 - Insider Monkey
INVIVYD INC (IVVD) Stock Chart - ChartMill
Invivyd, Inc. spotlights new data for solid organ transplant recipients in Boston - Traders Union
Invivyd Inc (IVVD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Invivyd Inc (IVVD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Invivyd Inc (IVVD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Invivyd Inc (IVVD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Invivyd Inc (IVVD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Invivyd completes Phase 3 COVID-19 antibody trial enrollment - grafa.com
H.C. Wainwright reiterates Invivyd stock rating on trial progress By Investing.com - Investing.com South Africa
Invivyd's Late-Stage Trial of Covid Vaccine Alternative Completes Enrollment; Shares Rise Pre-Bell - Moomoo
Invivyd completes enrollment in Phase 3 COVID antibody trial By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Invivyd stock rating on trial progress - Investing.com
Invivyd completes enrollment in Phase 3 COVID antibody trial - Investing.com
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine - The Manila Times
COVID antibody faces mRNA shots in Phase 3 side-effect study - Stock Titan
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
IVVD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
Invivyd, Inc. scrutinizes underexplored link between viral infections and cardiovascular inflammation - Traders Union
IVVD Stock Quote Price and Forecast - CNN
Invivyd doses first participants in phase 3 COVID-19 trial of VYD2311 - Contagion Live
Invivyd Inc (IVVD) Reports Clinical Progress. Stock Expected to Explode - Insider Monkey
Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential - Insider Monkey
IVVD,VCEL Revenue Breakdown - Finviz
IVVD Reiterated by BTIG -- Price Target Maintained at $10 - GuruFocus
Invivyd doses first participants in Phase 3 COVID-19 trial - Yahoo! Finance Canada
Invivyd doses first participants in Phase 3 LIBERTY trial - grafa.com
Small cap wrap: Royal Road Minerals, Miivo Holdings, Alvopetro, Arizona Gold & Silver... - Proactive financial news
Invivyd doses first participants in COVID-19 vaccine trial By Investing.com - Investing.com Australia
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-A - The Manila Times
Invivyd doses first participants in COVID-19 vaccine trial - Investing.com
New COVID shot alternative faces off with mRNA vaccine in Invivyd trial - Stock Titan
InvivydExpects Liberty Trial Topline Data In Q3 2026 - TradingView
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Invivyd Inc Stock (IVVD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Allen Robert D. III | Chief Scientific Officer |
Feb 17 '26 |
Sale |
1.54 |
18,189 |
28,004 |
133,879 |
| Green Julie | Chief Human Resources Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Green Julie | Chief Human Resources Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Duke William E. | Chief Financial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
107,717 |
| Duke William E. | Chief Financial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
128,681 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 18 '26 |
Sale |
1.58 |
20,964 |
33,077 |
117,717 |
| Lee Timothy Edward | Chief Commercial Officer |
Feb 17 '26 |
Sale |
1.54 |
19,663 |
30,273 |
138,681 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 18 '26 |
Sale |
1.58 |
34,939 |
55,127 |
181,736 |
| Andersen Jill | Chief Legal Officer, Secretary |
Feb 17 '26 |
Sale |
1.54 |
32,771 |
50,454 |
216,675 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):